fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone

DRUG2 trials

Sponsors

Fujian Shengdi Pharmaceutical Co., Ltd., Qilu Pharmaceutical Co., Ltd.

Conditions

Chemotherapy-Induced Nausea and VomitingPrevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy

Phase 3

Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors

CompletedNCT05509634

Fujian Shengdi Pharmaceutical Co., Ltd.Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy

Start: 2022-09-21End: 2023-08-30Updated: 2023-10-27

To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.

CompletedNCT07081256

Qilu Pharmaceutical Co., Ltd.Chemotherapy-Induced Nausea and Vomiting

Start: 2025-01-03End: 2025-10-15Updated: 2025-11-18

Related Papers

Efficacy and safety of mixed formulation aprepitant and palonosetron (QLM2010) for prevention of cisplatin-based highly emetogenic chemotherapy-induced nausea and vomiting: A multicenter, randomized, double-blind, double-dummy, positive-controlled phase III study.

Journal of Clinical Oncology2026-05-27